Efficacy Study of Tamsulosin and Tolterodine Treatment for Chronic Prostatitis
- Registration Number
- NCT00913315
- Lead Sponsor
- Chongqing Medical University
- Brief Summary
The purpose of this study is to determine whether tamsulosin and tolterodine are effective in the treatment of men with lower urinary tract symptoms and chronic prostatitis/chronic pelvic pain syndrome.
- Detailed Description
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common disorder in urological clinics. Most of the clinically CP/CPPS are to some extent associated with storage (irritative) symptoms, such as increased frequency, urgency, and nocturia, namely many patients with CP/CPPS have overactive bladder symptoms. Alpha-blocker therapy has been advocated as a treatment modality for CP/CPPS. Some trials showed a statistically and likely clinically significant treatment effect, while other trials showed no benefit. Therefore, tamsulosin combination with tolterodine treatment for CP/CPPS may be more effective than tamsulosin single.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Male
- Target Recruitment
- 30
- diagnosis of CP/CPPS based on the classification of US National Institutes of Health, aged 18-45 years
- total score of at least 12 on the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI)
- urinary score of at least 4 on the CPSI
- subjects who anticipate improving symptoms
- previous treatment with any other alpha-adrenergic receptor blocker and antimuscarinic agents for symptoms of CP/CPPS or for any other reason
- those who had had previous urinary tract infection with the last year
- those who had been treat or were taking medication that could affect lower urinary tract function
- those who met the criteria for chronic bacterial prostatitis after lower urinary tract localization studies
- those who had other significant medical problems
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description tamsulosin + placebo placebo - tolterodine + tamsulosin tolterodine - tolterodine + tamsulosin tamsulosin - tamsulosin + placebo tamsulosin -
- Primary Outcome Measures
Name Time Method National Institutes of Health Chronic Prostatitis Symptom Index 4 months
- Secondary Outcome Measures
Name Time Method International Index of Erectile Function 4 months Peak urinary flow rate 4 months
Trial Locations
- Locations (1)
Department of Urology, the First Affiliated Hospital of Chongqing Medical University
🇨🇳Chongqing, Chongqing, China